Navigation Links
Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
Date:5/22/2012

LEXINGTON, Mass., May 22, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,182,818, entitled "Methods of Using Anti-TNF Antibodies for Treating Radiation Damage to the Digestive Tract."

This patent provides broad coverage for using topically administered anti-TNF antibodies to treat radiation induced damage to the digestive tract.  Importantly, the patent specifically covers treatment of radiation induced mucositis, which is a common side effect of radiation therapy for cancer that often limits the effective radiation dose a patient can tolerate.  Avaxia has active research and development programs for its oral antibody AVX-470 for use in gastrointestinal acute radiation syndrome (GI-ARS) and mucositis. 

"This new patent emphasizes the innovative nature and broad applicability of our AVX Oral Antibody technology platform," stated Barbara Fox, PhD, CEO of Avaxia.  "For many cancer patients, the side effect of mucositis becomes intolerable, which causes terrible discomfort and may limit the dose of radiation that the patient receives to fight the disease.  Also, effective treatments for radiation damage are an important need for responding to potential terrorist attacks involving radioactive substances. Much of the morbidity and mortality associated with total body irradiation is due to damage to the GI tract. We are actively working to prove that AVX-470 can reduce that damage."

Avaxia has a $2.9 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop its oral anti-TNF antibody, AVX-470, for GI ARS. The work under this current contract explores the potential for the antibody to be further developed into a medical countermeasure to mitigate gastrointestinal damage from radiation exposure.

About Avaxia Biologics, Inc.: Avaxia is developing orally administered antibody therapeutics that act locally within the gastrointestinal (GI) tract.  Antibodies are widely used as therapeutics, with nearly $50 billion in annual sales worldwide.  Ordinary antibodies are not administered orally because they are destroyed in the GI tract.  In contrast, Avaxia has developed proprietary antibodies that are stable in the GI tract.  AVX Oral Antibodies make diseases with targets in the GI tract accessible to antibody therapeutics for the first time.  Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity. 


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
3. Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
4. Avaxia Biologics Barbara Fox Named one of Mass High Techs Women to Watch in 2012
5. Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
6. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
7. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
8. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
9. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
10. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
11. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
Breaking Medicine News(10 mins):